EP1984394A1 - Verfahren zur immunadsorption mittels autoantigenen - Google Patents
Verfahren zur immunadsorption mittels autoantigenenInfo
- Publication number
- EP1984394A1 EP1984394A1 EP07721862A EP07721862A EP1984394A1 EP 1984394 A1 EP1984394 A1 EP 1984394A1 EP 07721862 A EP07721862 A EP 07721862A EP 07721862 A EP07721862 A EP 07721862A EP 1984394 A1 EP1984394 A1 EP 1984394A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- disease
- syndrome
- autoimmune
- anemia
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
Definitions
- the invention relates to a novel process for the immunoadsorption of human or mammalian autoimmune diseases.
- autoimmune diseases have indication-specific autoantibodies (von Mühlen, CA, Tan E.M. (1995) Autoandibodies in the diagnosis of systemic rheumatic diseases, Semin Arthrithis Rheum., 24, 323-358). 5% of the world's population is affected by autoimmune diseases
- Such autoantibodies e.g. Cardiac structures have been described in recent years in dilated cardiomyopathy (DCM). This is due to the patients on "cardiotoxic antibodies", which are directed against the heart muscle cells. These autoantibodies could be eliminated by immunoadsorbent therapy (Dörffel WV, Felix SB, Wallukat G., et al., Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy, Circulation 1997, 95 (8): 1994-1997). Immunoadsorption therapy is a special blood wash that specifically purifies the blood of autoantibodies. DCM patients were treated with immunoadsorbent therapy at monthly intervals for three months and hemodynamics were analyzed using Swan Ganz monitoring. Increases in cardiac index, stroke volume index and left ventricular ejection fraction (echocardiography) were detected. At the same time, there was a decline in systemic vascular resistance.
- DCM dilated cardiomyopathy
- Immunoadsorption is a special method of adsorption that uses immunological properties; It is already used in the prior art for the therapy of patients
- RA and ITP are both autoimmune diseases characterized by the appearance of autoantibodies in high titers or serum concentrations, these autoantibodies are directly involved in the development of tissue damage and the progression of the disease.
- adsorbent materials e.g. in appropriate columns or
- Membrane modules used with immobilized protein A or protein G.
- Protein A or protein G (e.g., available from Miltenyi Biotec,
- IgG class immunoglobulins due to its high affinity for the Fc part of the IgG antibodies (class 1, 2 and 4). With less affinity they also bind certain IgG3, IgA and IgM antibodies.
- Immunoadsorption is a substitute for conventional plasmapheresis and appears to be an important adjunct to immunosuppressive therapy in SLE with difficult disease progression.
- the immunoadsorbent therapy as described in Artificial Organs, (1996), 986-990, uses the amino acids tryptophan or phenylalanine for attachment to the PVA gel particles and is therefore cumbersome and expensive. Moreover, with this therapy also substances that should not be removed from the plasma, such as IgG and IgM, separated in comparable amounts from the plasma.
- the invention therefore relates to a therapeutic method for the treatment and prophylaxis of autoimmune diseases, wherein an adsorption of autoantibodies from blood or blood plasma takes place extracorporeally by means of autoantigens (hereinafter: "inventive therapy").
- the invention also relates, in a preferred embodiment, to a method for producing an adsorbent for adsorbing autoantibodies in blood or blood plasma, comprising the following steps: a.) Providing a carrier material, b.) Immobilizing or fixing at least one autoantigen on this carrier material and bringing it into contact of the adsorbent with blood or blood plasma (hereinafter: "method according to the invention").
- the method according to the invention is carried out extracorporeally.
- the blood or blood plasma may continuously flow along the carrier material containing autoantigens.
- “Extracorporeal” in the sense of this invention means that the therapy according to the invention or the method according to the invention takes place outside the human body (synonymously: “ex vivo”).
- the therapy according to the invention is for the treatment or prophylaxis of autoimmune diseases.
- Autoimmune diseases are to be understood as those which have substantially indication-specific autoantibodies which are potentially suitable for harming the organism in any manner, in particular attacking the body's own tissue (for example due to overactive T cells).
- the following autoimmune diseases are not exhaustively included:
- AIHA autoimmune hemolytic
- Atherosclerosis arteriosclerosis, arteriosclerosis
- Diabetes mellitus type 1 insulin-dependent diabetes mellitus
- DCM Dilated Cardiomyopathy
- GAS Guillain-Barre syndrome
- Idiopathic pulmonary fibrosis IPF
- AIED Inner ear hearing loss, autoimmune
- Cardiomyopathy autoimmune cold agglutinin disease (see also: anemia, autoimmune hemolytic type of cold)
- MCTD Mixed Connective Tissue Disease
- Addison's disease see also: autoimmune adrenalitis; autoimmune
- Ankylosing spondylitis (ankylosing spondylitis)
- MS Multiple Sclerosis
- Encephalomyelitis disseminata Charcot
- Myasthenia gravis myasthenia; MG
- PGA Polyglandular autoimmune
- Polymyositis polyneuropathy chronic-inflammatory, demyelinating (see also: Chronic-inflammatory, demyelinating
- CIDP Primary biliary cirrhosis
- PBC Primary autoimmune cholangitis
- Reiter syndrome (Reiter's syndrome, urethro-conjunctival synovial syndrome) Rheumatic fever
- Takayasu's arteritis (Takayasu's disease, aortic arch syndrome)
- HLA various organs
- Hyperimmunization acute vascular rejection
- RA Rheumatoid arthritis
- ITP idiopathic thrombocytopenic purpura
- Another object of this invention relates to the identification of suitable autoantigens for the selective removal of autoantibodies.
- the autoantigens according to the invention can preferably be identified by means of protein micro and macroarrays.
- protein micro- and macro-arrays encompasses any arrangement of proteins on a surface of a solid support.
- array means synonymously “arrangement” and insofar as this "array” is used for the identification and characterization of proteins, in particular autoantigen, this is to be understood as an “assay” or “biochip” Macro “array” incubated with patient sera.
- the arrangement is such that the proteins represented on the array are in the form of a lattice.
- solid support includes embodiments such as a filter, a membrane, a magnetic bead, a silicon wafer, glass, metal, a chip, a mass spectrometric target or a matrix.
- a filter PVDF or nylon is preferred (e.g., Hybond N +, GE Health Gare).
- this corresponds to a grid having the size of a microtiter plate (96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
- this corresponds to a grid having the size of a microtiter plate (96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
- Protein microarrays and macroarrays enable the rapid and highly parallel detection of a large number of specifically binding analysis molecules in a single experiment. For the production of protein micro and macroarrays, it is necessary to have the required proteins available. Protein expression libraries have been established for this purpose.
- High-throughput cloning of defined open reading frames is a possibility (Heyman, JA, Cornthwaite, J., Foncerrada, L., Gilmore, JR, Gontang, E., Hartman, KJ, Hernandez, CL., Hood, R., Hill HM, Lee, WY, Marcil, R., Marsh, EJ, Mudd, KM, Patino, MJ, Purcell, TJ, Rowland, JJ, Sindici, ML and Hoeffler, JP (1999) Genome-scale cloning and expression of individual open reading frames using topoisomerase I mediated ligation Genome Res, 9, 383-392;
- some expression vectors have sequences for so-called affinity epitopes or proteins, which on the one hand allow the specific detection of the recombinant fusion proteins by means of an antibody directed against the affinity epitope, on the other hand, the specific purification via affinity chromatography (IMAC) allows.
- IMAC affinity chromatography
- some of these expression vectors preferably contain inducible promoters. The induction of
- Expression can be done, for example, by means of an inducer, such as IPTG.
- inducer such as IPTG.
- Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol 2003 Jan; 60 (5): 523-33).
- the expression product is preferably in the form of a fusion protein containing, for example, at least one affinity epitope or "tag".
- the day can be as c-myc, His-tag, Arg-tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or strep tag, HAT tag, NusA, S-tag, SBP tag, thioredoxin, DsbA, a fusion protein, preferably a cellulose binding domain, green fluorescent Protein, maltose binding protein, calmodulin binding protein, glutathione S-transferase or lacZ.
- the gene products of a cDNA expression library of human fetal brain tissue in the bacterial expression system Escherichia coli in high density format were placed on a membrane and successfully screened with different antibodies for specific protein-antibody interaction. It could be shown that the proportion of full-length proteins is at least 66%.
- the recombinant proteins of this library could be expressed and purified at high throughput. Brown P., Hu, Y., Shen, B., Halleck, A., Koundinya, M., Harlow, E. and LaBaer, J. (2002) Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Be U S A, 99, 2654-2659; Büssow (2000) supra; Lueking, A., Horn, M., Eickhoff, H., Büssow, K., Lehrach, H. and
- Expression libraries are known to the person skilled in the art, and these can be prepared according to standard works, such as Sambrook et al., Molecular Cloning, Laboratory Handbook, 2nd edition (1989), CSH press, CoId Spring Harbor, New York Further preferred are expression libraries which are tissue-specific.
- expression libraries which can be obtained by exon trapping are also included in the invention, and instead of an expression library it is possible to speak synonymously of an expression library.
- protein micro and macroarrays or corresponding expression libraries which do not provide redundancy (Üniclone® biochips) and can be prepared according to the teachings of WO 99/57311 and WO 99/57312. These preferred Uniclone biochips have a high content of non-defective, fully expressed proteins of a cDNA expression library (see examples).
- Autoantigens can be safely identified (screened), cultured and purified (protein production) and further characterized. For this, sera, blood or blood plasma from patients are given via a protein micro and macroarray (see examples).
- potential autoantigens are identified by a macroarray (e.g., a human cDNA expression library containing more than 10,000 clones) that are confirmed by a microarray (selection of potential clones) using patient sera (containing autoantibodies).
- the invention also relates to a method for
- Autoantigen consisting of the following steps: a.) Incubation of a first array containing proteins with
- the first array consists of a cDNA expression library (described, supra) with at least 10,000 clones or proteins. Furthermore, it is preferred that the first array in a) has redundant clones or proteins.
- Re-Arraying means that identified proteins or clones are rearranged to a second array.
- the visualization of such autoantibody-autoantigen interactions can be carried out, for example, by means of fluorescence labeling, biotinylation or radio-isotope labeling in a customary manner.
- a readout is e.g. by means of a microarray laser scanner.
- autoantigens can be isolated, enriched or cloned by conventional methods.
- the therapy according to the invention relates to those autoantigens obtainable from a screening method by means of any analytical method, in particular such as protein microarrays and macroarrays, ELISA and / or BIAcore.
- the therapy according to the invention relates to such
- Carrier materials which are able to fix or immobilize autoantigens.
- adsorbers which are able to fix or immobilize autoantigens.
- the adsorber is biocompatible (Jayabalan M.
- Suitable carrier materials are such as, but not limited to, glass, carbohydrates and modified carbohydrates, sepharose, proteins such as collagen or gelatin, silica or organic matrices, polymers such as polyamides, PVDF, nylon, nitrocellulose and others.
- the carrier material may be in the form of spherical, unaggregated particles, so-called beads, fibers or a membrane, wherein a porosity of the matrix increases the surface area.
- the porosity can be achieved, for example, in the customary manner by adding pore formers, such as cyclohexanol or 1-dodecanol, to the reaction mixture of the suspension polymerization.
- the autoantigens can be applied in a known and arbitrary manner to the carrier material.
- the autoantigen is a fusion protein (examples, supra) which is suitable for adhering to the carrier material.
- individual autoantigens can be identified and used in the therapeutic method by means of the provided protein micro and macroarrays for the patient. If only 50-40% or even 20-10% of the autoantigens of an autoimmune disease are qualitatively identified and specific, a significant or significant therapeutic success already arises. For example, autoantigens are known and active for MS 20. Of these, 8 or less may already lead to therapeutic success.
- the invention also relates to a method wherein non-individual indication specific autoantigens are used by a particular selection of patients for the therapy of any entity (ever greater than said particular selection) of patients according to the invention.
- the invention relates to a device or kit consisting of a carrier material containing selected autoantigens including customary agents, in particular components for carrying out the therapy according to the invention or blood washing / immunoadsorption therapy and the method according to the invention.
- a carrier material containing selected autoantigens including customary agents in particular components for carrying out the therapy according to the invention or blood washing / immunoadsorption therapy and the method according to the invention.
- Corresponding known devices for blood washing or immunoadsorption therapy can be adapted accordingly.
- the invention relates to the use of a carrier material containing autoantigens for
- the invention relates to the use of a carrier material containing autoantigens for the adsorption of autoantibodies from blood or blood plasma of patients with autoimmune diseases.
- the patient is returned to the outlet of the device of the carrier material is preferably a filter.
- This is preferably a particle filter of suitable size.
- the expression clones expressing the autoantigen identified in Example 1 were re-arrayed (ie positively identified clones were seeded onto a second array), and the expression products were purified by IMAC.
- the purified proteins were first checked by SDS gel electrophoresis for their purity and additionally analyzed by mass spectrometry. The thus purified and characterized proteins were then spotted onto a suitable carrier to make a microarray.
- the proteins produced in Example 1 were transferred to nitrocellulose-coated carrier surfaces using a spotting robot.
- the protein biochip contained additional control proteins.
- Process control human IgG and mouse IgG were used. These immunoglobulins were bound by the secondary antibodies required for the detection of human autoantibodies and can be used in addition to the process control for normalization ("inter chip normalization") . The process control proteins were also distributed over several quadrants of the chip. Intrafield "analysis used to check the homogeneity of the surface or incubation reaction. With appropriate bioinformatic tools (reviewed in: Hamacher, Michael / Marcus, Katrin / Stühler, Kai / van Hall, Andre / Warscheid, Bettina / Meyer, Helmut E. (ed.), Proteomics in Drug Research, Methods and Principles in Medicinal Chemistry (Volume 28) Edited by Mannhold, Raimund / Kubinyi, Hugo / Folkers, Gerd) can be based on the
- NAAs natural autoantigens
- stathmin or tubulin which can be found in approximately 90% of all sera (regardless of whether they are sick or healthy)
- BSA non-epitope-tagged, non-human proteins
- lysozyme were applied to the protein biochip. These were used to determine the reference value of the background. All of these proteins are present in duplicate spotted (and sometimes on several quadrants) on the protein biochip.
- the protein biochips prepared in Example 2 are used in Example 5.
- the patient selection was carried out considering firstly the age and sex of the patients
- the sera collection was carried out according to a standardized protocol (decrease, centrifugation, aliquoting, flash freezing and storage at -80 0 C), with a total of 15 ml of whole blood were removed for sera extraction. In total, several hundred samples per patient (RA patient) and control group were collected and examined. The sample data (sample and patient ID, date of acceptance, administration of medication) were recorded in a standardized sample sheet at the time of sample acceptance and corresponding samples were collected.
- a database model was designed. Subsequently, this model was implemented and created a database-based server-client software. In this database, the data of each clone in a collection was collected and archived. For example, the sequencing information, the gene ontology classification of a corresponding protein product, the expression rate and the quality control information such as ID gel and mass spectrometric results were stored and analyzed using various filters and methods
- RA and MS patient serums were cataloged and the corresponding data were fed into the database in an appropriate format.
- the patient sera are then examined on the various screening tools.
- Proteins (Example 1) were screened first using high density filters of expression libraries. Such high density filters contain a large collection of proteins with at least 10,000 different proteins.
- such a screening approach has been successfully described (Gutjahr, C, et al., Mouse protein arrays from a T (H) cDNA library for antibody screening and serum. Profiling.
- Genomics, 2005. 85 (3): p. 285-96 The proteins identified in this screening were incorporated into the collection of 2000 and 4000 proteins, respectively.
- high density filters of the human fetal brain expression library (Büssow, K., et al., A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library, Nucleic Acids Research, 1998. 26 (21): p. 5007-5008), as well as the T lymphocyte specific expression library.
- Chip production data production batch, protein batch
- patient sample data patient sample data
- associated raw data from the image evaluation in the database taken.
- bioinformatic evaluation is carried out taking into account the correlation of the patient data with the screening data (example 6). This bioinformatic study results in the selection of putatively relevant protein antigens. The corresponding expression clones of these protein antigens are backvalidated as described in Example 8.
- a first test set is used to test various normalization methods and statistical tests that have been described for the field of DNA microarrays with regard to their suitability for protein microarrays.
- the putative biomarkers determined from these analyzes are then examined again in Example 5 with different test sera from patients with other autoimmune diseases such as Sjögren's syndrome, SLE or alopecia areata.
- the proteomes were analyzed using state-of-the-art technology. DIGE fluorescence difference gel electrophoresis shown and compared.
- the revalidation of the selected protein antigens is done with a different aliquot of the same serum by Western immunoblot.
- the corresponding antigens were prepared on an analytical scale.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006003782A DE102006003782A1 (de) | 2006-01-25 | 2006-01-25 | Immunadsorptionstherapie mittels Autoantigenen |
PCT/DE2007/000139 WO2007085240A1 (de) | 2006-01-25 | 2007-01-24 | Verfahren zur immunadsorption mittels autoantigenen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1984394A1 true EP1984394A1 (de) | 2008-10-29 |
Family
ID=38042753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07721862A Withdrawn EP1984394A1 (de) | 2006-01-25 | 2007-01-24 | Verfahren zur immunadsorption mittels autoantigenen |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090246203A1 (de) |
EP (1) | EP1984394A1 (de) |
DE (1) | DE102006003782A1 (de) |
WO (1) | WO2007085240A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8865172B2 (en) * | 2000-05-08 | 2014-10-21 | Advanced Extravascular Systems, Inc. | Method for reducing the number of unwanted molecules in bodily fluids |
EP2056110A1 (de) * | 2007-10-31 | 2009-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Biomarker zur Vorhersage einer Reaktionsfähigkeit auf eine Anti-TNF-alpha-Behandlung |
EP2110140A1 (de) | 2008-04-18 | 2009-10-21 | Gert Baumann | Behandlung von Thromboangiitis obliterans mittels Autoantikörperentfernung |
US20150290386A1 (en) * | 2014-04-10 | 2015-10-15 | Xianfeng Frank Zhao | Extracorporeal autoimmune solution therapy (east) |
EP3477300A1 (de) * | 2017-10-25 | 2019-05-01 | Euroimmun Medizinische Labordiagnostika AG | Zellulose-basierter immunadsorber |
SG10201908826UA (en) | 2018-10-22 | 2020-05-28 | Euroimmun Medizinische Labordiagnostika Ag | Diagnosis of blistering autoimmune diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991017171A1 (en) * | 1990-05-07 | 1991-11-14 | Oklahoma Medical Research Foundation | NUCLEOTIDE SEQUENCE ENCODING A 52 kDa Ro/SSA AUTOANTIGEN |
AU671589B2 (en) * | 1991-05-15 | 1996-09-05 | Board Of Regents Of The University Of Washington, The | Cloning and expression of human islet glutamic acid decarboxylase autoantigen |
US20020172676A1 (en) * | 2001-05-16 | 2002-11-21 | George Jackowski | Method of treatment of alzheimer's disease and device therefor |
DE102004056794B4 (de) * | 2004-11-24 | 2010-08-26 | Protagen Ag | Verwendung einer Anordnung und Verfahren zur Validierung von Bindern |
-
2006
- 2006-01-25 DE DE102006003782A patent/DE102006003782A1/de not_active Ceased
-
2007
- 2007-01-24 EP EP07721862A patent/EP1984394A1/de not_active Withdrawn
- 2007-01-24 WO PCT/DE2007/000139 patent/WO2007085240A1/de active Application Filing
- 2007-01-24 US US12/162,240 patent/US20090246203A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2007085240A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20090246203A1 (en) | 2009-10-01 |
WO2007085240A1 (de) | 2007-08-02 |
DE102006003782A1 (de) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230417743A1 (en) | Antibody-linked immuno-sedimentation agent and method of isolating a target from a sample using same | |
EP1984394A1 (de) | Verfahren zur immunadsorption mittels autoantigenen | |
Nyland et al. | Guillain‐Barré syndrome: Demonstration of antibodies to peripheral nerve tissue | |
Woo et al. | Characterization and modulation of surface charges to enhance extracellular vesicle isolation in plasma | |
WO1999056126A2 (de) | Immunadsorptionsmatrix, verfahren zu ihrer herstellung und ihre verwendung | |
EP0937982B1 (de) | Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis | |
EP1386160B1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
WO2003024587A2 (de) | Verfahren zur aufreinigung von vollblut | |
US11162880B2 (en) | Particle size purification method and devices | |
CN109593710B (zh) | 快速、高通量分离收集免疫原特异性b细胞的方法 | |
DE102011008153B4 (de) | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein | |
EP3194436B1 (de) | Monoklonaler antikörper gegen humanes tau-protein | |
EP1003787A2 (de) | Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen | |
US7682793B2 (en) | Immune complexes | |
JPS6260106B2 (de) | ||
US20180303998A1 (en) | Novel Treatment Method for Cockayne Syndrome | |
Sundharagiati et al. | A CLINICAL AND EXPERIMENTAL STUDY OF THE ERYTHRO-CYTE ULTRASTRUCTURE MEMBRANE WITH THE ELECTRON MICROSCOPE | |
WO2003025568A9 (de) | Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation | |
DE4112999A1 (de) | Verfahren und nachweismittel zum nachweis von autoantikoerpern, die als reaktion auf eine infektion mit dem epstein-barr virus gebildet wurden | |
WO2008092442A1 (de) | Stratifizierung und therapiesteuerung eines patienten mittels proteinbiochips | |
EP1410037A2 (de) | Verfahren zur identifikation von immunreaktiven epitopen auf proteinen und verwendung der epitope zu prophylaktischen und therapeutischen zwecken | |
US20040208865A1 (en) | Immune complexes | |
Vandenbark et al. | CSF autoantibodies detect brain antigens | |
RU2646807C1 (ru) | Способ выделения аутоантител подклассов иммуноглобулина G к иммунорегуляторному цитокину фактору некроза опухоли | |
EP0141939A2 (de) | Verfahren zur Herstellung von natürlichem Immunoadsorbens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080825 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GUTJAHR, CLAUDIA Inventor name: LUEKING, ANGELIKA Inventor name: SCHEER, CHRISTIAN Inventor name: TRAPPE, VERENA Inventor name: SCHULTE, KIRSTEN |
|
17Q | First examination report despatched |
Effective date: 20090706 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100119 |